The author Arnulfo E. Morales-Galicia gratefully acknowledges the Programa Nacional de Servicio Social en Investigación of the Dirección General de Calidad y Educación en Salud, Secretaría de Salud, México, for the valuable opportunity to carry out this internship, which substantially contributed to the development and completion of this research work.
Author contributions
AEMG: Visualization, Investigation, Writing—original draft, Writing—review & editing. MNRS: Visualization, Writing—review & editing. MMRM: Investigation, Writing—original draft, Writing—review & editing. NMS: Conceptualization, Writing—original draft, Writing—review & editing, Supervision. All the authors read and approved the submitted version.
Conflicts of interest
Nahum Méndez-Sánchez, who is the Associate Editor and Guest Editor of Exploration of Digestive Diseases, was not involved in the decision-making or the review process of this manuscript. The other authors declare no conflicts of interest.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
Weissenborn K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles.Drugs. 2019;79:5–9. [DOI] [PubMed] [PMC]
Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications.Cell Metab. 2022;34:1700–18. [DOI] [PubMed]
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy.J Hepatol. 2020;72:558–77. [DOI] [PubMed]
Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease.Nat Rev Microbiol. 2023;21:719–33. [DOI] [PubMed] [PMC]
Yokoyama K, Sakamaki A, Takahashi K, Naruse T, Sato C, Kawata Y, et al. Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function.PLoS One. 2022;17:e0264459. [DOI] [PubMed] [PMC]
Lu H, Zhang H, Wu Z, Li L. Microbiota-gut-liver-brain axis and hepatic encephalopathy.Microbiome Res Rep. 2024;3:17. [DOI] [PubMed] [PMC]
Mancini A, Campagna F, Amodio P, Tuohy KM. Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy.Food Funct. 2018;9:1373–88. [DOI] [PubMed]
Zhu R, Liu L, Zhang G, Dong J, Ren Z, Li Z. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis.Biosci Rep. 2023;43:BSR20222524. [DOI] [PubMed] [PMC]
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy.J Hepatol. 2022;77:807–24. [DOI] [PubMed]
Rudler M, Weiss N, Bouzbib C, Thabut D. Diagnosis and Management of Hepatic Encephalopathy.Clin Liver Dis. 2021;25:393–417. [DOI] [PubMed]
Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.Clin Gastroenterol Hepatol. 2015;13:2048–61. [DOI] [PubMed] [PMC]
Higuera-de-la-Tijera F, Velarde-Ruiz Velasco JA, Raña-Garibay RH, Castro-Narro GE, Abdo-Francis JM, Moreno-Alcántar R, et al. Current vision on diagnosis and comprehensive care in hepatic encephalopathy.Rev Gastroenterol Mex (Engl Ed). 2023;88:155–74. [DOI] [PubMed]
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.Hepatology. 2014;60:715–35. [DOI] [PubMed]
Harris KB, Gonzalez HC, Gordon SC. The Health Care Burden of Hepatic Encephalopathy.Clin Liver Dis. 2024;28:265–72. [DOI] [PubMed]
Lv XH, Lu Q, Deng K, Yang JL, Yang L. Prevalence and Characteristics of Covert/Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis: A Systematic Review and Meta-Analysis.Am J Gastroenterol. 2024;119:690–9. [DOI] [PubMed]
Louissaint J, Deutsch-Link S, Tapper EB. Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy.Clin Gastroenterol Hepatol. 2022;20:S1–8. [DOI] [PubMed] [PMC]
Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy—a double-blind placebo-controlled study.Aliment Pharmacol Ther. 2011;34:853–61. [DOI] [PubMed]
Coronel-Castillo CE, Contreras-Carmona J, Frati-Munari AC, Uribe M, Méndez-Sánchez N. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.Rev Gastroenterol Mex (Engl Ed). 2020;85:56–68. Spanish. [DOI] [PubMed]
Vidal-Cevallos P, Chávez-Tapia NC, Uribe M. Current approaches to hepatic encephalopathy.Ann Hepatol. 2022;27:100757. [DOI] [PubMed]
Thabut D, Bouzbib C, Meunier L, Haas M, Weiss N, Louvet A, et al.; Association Française pour l’Etude du Foie (AFEF) group of experts of HE recommendations. Diagnosis and management of hepatic encephalopathy: The French recommendations.Liver Int. 2023;43:750–62. [DOI] [PubMed]
Needham E, Webb G. Hepatic encephalopathy: a neurologist's perspective.Pract Neurol. 2024;24:200–6. [DOI] [PubMed]
Nardelli S, Gioia S, Faccioli J, Riggio O, Ridola L. Hepatic encephalopathy - recent advances in treatment and diagnosis.Expert Rev Gastroenterol Hepatol. 2023;17:225–35. [DOI] [PubMed]
Butterworth RF. Hepatic Encephalopathy in Cirrhosis: Pathology and Pathophysiology.Drugs. 2019;79:17–21. [DOI] [PubMed] [PMC]
Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications: A Review.JAMA. 2023;329:1589–602. [DOI] [PubMed] [PMC]
Chen A, Tait C, Minacapelli C, Rustgi V. Pathophysiology of Hepatic Encephalopathy: A Framework for Clinicians.Clin Liver Dis. 2024;28:209–24. [DOI] [PubMed]
Ramírez-Mejía MM, Castillo-Castañeda SM, Pal SC, Qi X, Méndez-Sánchez N. The Multifaceted Role of Bilirubin in Liver Disease: A Literature Review.J Clin Transl Hepatol. 2024;12:939–48. [DOI] [PubMed] [PMC]
Jaffe A, Lim JK, Jakab SS. Pathophysiology of Hepatic Encephalopathy.Clin Liver Dis. 2020;24:175–88. [DOI] [PubMed]
Zielińska M, Popek M, Albrecht J. Neuroglia in hepatic encephalopathy.Handb Clin Neurol. 2025;210:191–212. [DOI] [PubMed]
Sen BK, Pan K, Chakravarty A. Hepatic Encephalopathy: Current Thoughts on Pathophysiology and Management.Curr Neurol Neurosci Rep. 2025;25:28. [DOI] [PubMed]
González-Regueiro JA, Higuera-de la Tijera MF, Moreno-Alcántar R, Torre A. Pathophysiology of hepatic encephalopathy and future treatment options.Rev Gastroenterol Mex (Engl Ed). 2019;84:195–203. [DOI] [PubMed]
Castillo-Castañeda SM, Rivera-Espinosa L, Gómez-Garduño J, Cordova-Gallardo J, Chávez-Pacheco JL, Méndez-Sánchez N. Identification and quantification of the molecular species of bilirubin BDG, BMG and UCB by LC‒MS/MS in hyperbilirubinemic human serum.PLoS One. 2024;19:e0313044. [DOI] [PubMed] [PMC]
Pabst O, Hornef MW, Schaap FG, Cerovic V, Clavel T, Bruns T. Gut-liver axis: barriers and functional circuits.Nat Rev Gastroenterol Hepatol. 2023;20:447–61. [DOI] [PubMed]
Kiseleva YV, Zharikova TS, Maslennikov RV, Temirbekov SM, Olsufieva AV, Polyakova OL, et al. Gut Microbiota and Liver Regeneration: A Synthesis of Evidence on Structural Changes and Physiological Mechanisms.J Clin Exp Hepatol. 2024;14:101455. [DOI] [PubMed]
Milosevic I, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, et al. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.Int J Mol Sci. 2019;20:395. [DOI] [PubMed] [PMC]
El-Sayed A, Aleya L, Kamel M. Microbiota’s role in health and diseases.Environ Sci Pollut Res Int. 2021;28:36967–83. [DOI] [PubMed] [PMC]
Hsu CL, Duan Y, Fouts DE, Schnabl B. Intestinal virome and therapeutic potential of bacteriophages in liver disease.J Hepatol. 2021;75:1465–75. [DOI] [PubMed] [PMC]
Gaspar BS, Roşu OA, Enache RM, Manciulea Profir M, Pavelescu LA, Creţoiu SM. Gut Mycobiome: Latest Findings and Current Knowledge Regarding Its Significance in Human Health and Disease.J Fungi (Basel). 2025;11:333. [DOI] [PubMed] [PMC]
Zhang L, Zhan H, Xu W, Yan S, Ng SC. The role of gut mycobiome in health and diseases.Therap Adv Gastroenterol. 2021;14:17562848211047130. [DOI] [PubMed] [PMC]
Wang Y, Liu Y. Gut-liver-axis: Barrier function of liver sinusoidal endothelial cell.J Gastroenterol Hepatol. 2021;36:2706–14. [DOI] [PubMed]
De Cól JP, de Lima EP, Pompeu FM, Cressoni Araújo A, de Alvares Goulart R, Bechara MD, et al. Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update.Int J Mol Sci. 2024;25:3694. [DOI] [PubMed] [PMC]
Anand S, Mande SS. Host-microbiome interactions: Gut-Liver axis and its connection with other organs.NPJ Biofilms Microbiomes. 2022;8:89. [DOI] [PubMed] [PMC]
Albhaisi SAM, Bajaj JS, Sanyal AJ. Role of gut microbiota in liver disease.Am J Physiol Gastrointest Liver Physiol. 2020;318:G84–98. [DOI] [PubMed]
El-Mowafy M, Elgaml A, El-Mesery M, Sultan S, Ahmed TAE, Gomaa AI, et al. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection.Biology (Basel). 2021;10:55. [DOI] [PubMed] [PMC]
Marascio N, De Caro C, Quirino A, Mazzitelli M, Russo E, Torti C, et al. The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview.J Clin Med. 2022;11:5936. [DOI] [PubMed] [PMC]
Chopyk DM, Grakoui A. Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.Gastroenterology. 2020;159:849–63. [DOI] [PubMed] [PMC]
De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective.Cells. 2021;10:2959. [DOI] [PubMed] [PMC]
Philips CA, Augustine P. Gut Barrier and Microbiota in Cirrhosis.J Clin Exp Hepatol. 2022;12:625–38. [DOI] [PubMed] [PMC]
Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN. Intestinal barrier function in health and gastrointestinal disease.Neurogastroenterol Motil. 2012;24:503–12. [DOI] [PubMed] [PMC]
Duarte MJ, Tien PC, Somsouk M, Price JC. The human microbiome and gut-liver axis in people living with HIV.Curr HIV/AIDS Rep. 2023;20:170–80. [DOI] [PubMed] [PMC]
Di Tommaso N, Santopaolo F, Gasbarrini A, Ponziani FR. The Gut-Vascular Barrier as a New Protagonist in Intestinal and Extraintestinal Diseases.Int J Mol Sci. 2023;24:1470. [DOI] [PubMed] [PMC]
Liu S, Song P, Sun F, Ai S, Hu Q, Guan W, et al. The concept revolution of gut barrier: from epithelium to endothelium.Int Rev Immunol. 2021;40:401–8. [DOI] [PubMed]
Salvo Romero E, Alonso Cotoner C, Pardo Camacho C, Casado Bedmar M, Vicario M. The intestinal barrier function and its involvement in digestive disease.Rev Esp Enferm Dig. 2015;107:686–96. [DOI] [PubMed]
Shen TD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver.Liver Transpl. 2018;24:539–50. [DOI] [PubMed]
Giuffrè M, Moretti R. The Gut-Liver-Brain Axis: From the Head to the Feet.Int J Mol Sci. 2023;24:15662. [DOI] [PubMed] [PMC]
Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases.Cell Mol Immunol. 2021;18:4–17. [DOI] [PubMed] [PMC]
Ding JH, Jin Z, Yang XX, Lou J, Shan WX, Hu YX, et al. Role of gut microbiota via the gut-liver-brain axis in digestive diseases.World J Gastroenterol. 2020;26:6141–62. [DOI] [PubMed] [PMC]
Bajaj JS. The role of microbiota in hepatic encephalopathy.Gut Microbes. 2014;5:397–403. [DOI] [PubMed] [PMC]
Rai R, Saraswat VA, Dhiman RK. Gut microbiota: its role in hepatic encephalopathy.J Clin Exp Hepatol. 2015;5:S29–36. [DOI] [PubMed] [PMC]
Sung CM, Lin YF, Chen KF, Ke HM, Huang HY, Gong YN, et al. Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome.Cell Mol Gastroenterol Hepatol. 2019;8:301–18.e2. [DOI] [PubMed] [PMC]
Sun T, Du H, Li Z, Xiong J, Liu Y, Li Y, et al. Decoding the contributions of gut microbiota and cerebral metabolism in acute liver injury mice with and without cognitive dysfunction.CNS Neurosci Ther. 2023;29 Suppl 1:31–42. [DOI] [PubMed] [PMC]
Luo M, Xin RJ, Hu FR, Yao L, Hu SJ, Bai FH. Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy via the gut-liver-brain axis.World J Gastroenterol. 2023;29:144–56. [DOI] [PubMed] [PMC]
Chen Z, Ruan J, Li D, Wang M, Han Z, Qiu W, et al. The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy.Front Cell Infect Microbiol. 2021;10:595759. [DOI] [PubMed] [PMC]
Rocco A, Sgamato C, Compare D, Coccoli P, Nardone OM, Nardone G. Gut Microbes and Hepatic Encephalopathy: From the Old Concepts to New Perspectives.Front Cell Dev Biol. 2021;9:748253. [DOI] [PubMed] [PMC]
Wu JL, Chen JW, Huang MS, Deng XY, Deng JJ, Lau TY, et al. The causal effect of gut microbiota on hepatic encephalopathy: a mendelian randomization analysis.BMC Med Genomics. 2024;17:216. [DOI] [PubMed] [PMC]
Jinato T, Sikaroodi M, Fagan A, Sterling RK, Lee H, Puri P, et al. Alterations in gut virome are associated with cognitive function and minimal hepatic encephalopathy cross-sectionally and longitudinally in cirrhosis.Gut Microbes. 2023;15:2288168. [DOI] [PubMed] [PMC]
Bajaj JS, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.Gut. 2021;70:1162–73. [DOI] [PubMed]
Li Y, Liu D, He Y, Zhang Z, Zeng A, Fan C, et al. The signatures and crosstalk of gut microbiome, mycobiome, and metabolites in decompensated cirrhotic patients.Front Microbiol. 2024;15:1443182. [DOI] [PubMed] [PMC]
Lin X, Yu Z, Liu Y, Li C, Hu H, Hu JC, et al. Gut-X axis.Imeta. 2025;4:e270. [DOI] [PubMed] [PMC]
Sivaprasadan S, Anila KN, Nair K, Mallick S, Biswas L, Valsan A, et al. Microbiota and Gut-Liver Axis: An Unbreakable Bond?Curr Microbiol. 2024;81:193. [DOI] [PubMed]
He X, Hu M, Xu Y, Xia F, Tan Y, Wang Y, et al. The gut-brain axis underlying hepatic encephalopathy in liver cirrhosis.Nat Med. 2025;31:627–38. [DOI] [PubMed]
Pan L, Xie L, Yang W, Feng S, Mao W, Ye L, et al. The role of brain-liver-gut Axis in neurological disorders.Burns Trauma. 2025;13:tkaf011. [DOI] [PubMed] [PMC]
Shahbazi A, Sepehrinezhad A, Vahdani E, Jamali R, Ghasempour M, Massoudian S, et al. Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain.Biomedicines. 2023;11:1272. [DOI] [PubMed] [PMC]
Giuli L, Maestri M, Santopaolo F, Pompili M, Ponziani FR. Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease.Metabolites. 2023;13:772. [DOI] [PubMed] [PMC]
Solanki R, Karande A, Ranganathan P. Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration.Front Neurol. 2023;14:1149618. [DOI] [PubMed] [PMC]
Mannaioni G, Carpenedo R, Corradetti R, Carlà V, Venturini I, Baraldi M, et al. Tryptophan metabolism and hepatic encephalopathy. Studies on the sedative properties of oxindole.Adv Exp Med Biol. 1999;467:155–67. [PubMed]
Li X, Zhang B, Hu Y, Zhao Y. New Insights Into Gut-Bacteria-Derived Indole and Its Derivatives in Intestinal and Liver Diseases.Front Pharmacol. 2021;12:769501. [DOI] [PubMed] [PMC]
Jiang X, Xu L, Tang L, Liu F, Chen Z, Zhang J, et al. Role of the indoleamine-2,3-dioxygenase/kynurenine pathway of tryptophan metabolism in behavioral alterations in a hepatic encephalopathy rat model.J Neuroinflammation. 2018;15:3. [DOI] [PubMed] [PMC]
Zeng G, Krishnamurthy S, Staats Pires A, Guller A, Chaganti J, Tun N, et al. Activation of the kynurenine pathway identified in individuals with covert hepatic encephalopathy.Hepatol Commun. 2024;8:e0559. [DOI] [PubMed] [PMC]
Won SM, Oh KK, Gupta H, Ganesan R, Sharma SP, Jeong JJ, et al. The Link between Gut Microbiota and Hepatic Encephalopathy.Int J Mol Sci. 2022;23:8999. [DOI] [PubMed] [PMC]
Wang Y, Yang L, Shang Y, Huang Y, Ju C, Zheng H, et al. Identifying Minimal Hepatic Encephalopathy: A New Perspective from Magnetic Resonance Imaging.J Magn Reson Imaging. 2025;61:11–24. [DOI] [PubMed]
Yakut A. Gut microbiota in the development and progression of chronic liver diseases: Gut microbiota-liver axis.World J Hepatol. 2025;17:104167. [DOI] [PubMed] [PMC]
Román E, Nieto JC, Gely C, Vidal S, Pozuelo M, Poca M, et al. Effect of a Multistrain Probiotic on Cognitive Function and Risk of Falls in Patients With Cirrhosis: A Randomized Trial.Hepatol Commun. 2019;3:632–45. [DOI] [PubMed] [PMC]
Laghi L, Román E, Lan Q, Nieto JC, Canalda-Baltrons A, Poca M, et al. A multistrain probiotic increases the serum glutamine/glutamate ratio in patients with cirrhosis: a metabolomic analysis.Hepatol Commun. 2023;7:e0072. [DOI] [PubMed] [PMC]
Gairing SJ, Schleicher EM, Labenz C. Diabetes mellitus—risk factor and potential future target for hepatic encephalopathy in patients with liver cirrhosis?Metab Brain Dis. 2023;38:1691–700. [DOI] [PubMed] [PMC]
Bajaj JS, Fagan A, Gavis EA, Sterling RK, Gallagher ML, Lee H, et al. Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial.J Hepatol. 2025;83:81–91. [DOI] [PubMed]
Monteiro-Cardoso VF, Corlianò M, Singaraja RR. Bile Acids: A Communication Channel in the Gut-Brain Axis.Neuromolecular Med. 2021;23:99–117. [DOI] [PubMed]
DeMorrow S. Bile Acids in Hepatic Encephalopathy.J Clin Exp Hepatol. 2019;9:117–24. [DOI] [PubMed] [PMC]
Balzano T, Llansola M, Arenas YM, Izquierdo-Altarejos P, Felipo V. Hepatic encephalopathy: investigational drugs in preclinical and early phase development.Expert Opin Investig Drugs. 2023;32:1055–69. [DOI] [PubMed]
Munk Lauridsen M, Jonasson E, Bajaj JS. Microbial Approaches to Treat and Prevent Hepatic Encephalopathy.Gastroenterol Clin North Am. 2025;54:429–51. [DOI] [PubMed]
Manzhalii E, Moyseyenko V, Kondratiuk V, Molochek N, Falalyeyeva T, Kobyliak N. Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment.World J Hepatol. 2022;14:634–46. [DOI] [PubMed] [PMC]
Wang MW, Ma WJ, Wang Y, Ma XH, Xue YF, Guan J, et al. Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota.Front Microbiol. 2023;14:1091167. [DOI] [PubMed] [PMC]
Jia W, Li Y, Cheung KCP, Zheng X. Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis.Sci China Life Sci. 2024;67:865–78. [DOI] [PubMed]
Buckholz AP, Brown RS Jr. Future Therapies of Hepatic Encephalopathy.Clin Liver Dis. 2024;28:331–44. [DOI] [PubMed] [PMC]
Odenwald MA, Lin H, Lehmann C, Dylla NP, Cole CG, Mostad JD, et al. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.Nat Microbiol. 2023;8:2033–49. [DOI] [PubMed] [PMC]
Sadri M, Shafaghat Z, Roozbehani M, Hoseinzadeh A, Mohammadi F, Arab FL, et al. Effects of Probiotics on Liver Diseases: Current In Vitro and In Vivo Studies.Probiotics Antimicrob Proteins. 2025;17:1688–710. [DOI] [PubMed]
Philips CA, Augustine P, Yerol PK, Ramesh GN, Ahamed R, Rajesh S, et al. Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease.J Clin Transl Hepatol. 2020;8:87–99. [DOI] [PubMed] [PMC]
Campion D, Giovo I, Ponzo P, Saracco GM, Balzola F, Alessandria C. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.World J Hepatol. 2019;11:489–512. [DOI] [PubMed] [PMC]
Zhou Z, Li K, Guo J, Wang Y, Wei Y, Duan J, et al. Green Tea Catechin EGCG Ameliorates Thioacetamide-Induced Hepatic Encephalopathy in Rats via Modulation of the Microbiota-Gut-Liver Axis.Mol Nutr Food Res. 2023;67:e2200821. [DOI] [PubMed]
Casirola DM, Ferraris RP. α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.Metabolism. 2006;55:832–41. [DOI] [PubMed]
Hamada Y, Goto M, Nishimura G, Nagasaki H, Seino Y, Kamiya H, et al. The alpha-glucosidase inhibitor miglitol increases hepatic CYP7A1 activity in association with altered short-chain fatty acid production in the gut of obese diabetic mice.Metabol Open. 2020;5:100024. [DOI] [PubMed] [PMC]
Yen FS, Hou MC, Wei JC, Shih YH, Hsu CY, Hsu CC, et al. Liver-related long-term outcomes of alpha-glucosidase inhibitors in patients with diabetes and liver cirrhosis.Front Pharmacol. 2022;13:1049094. [DOI] [PubMed] [PMC]
McMillin M, Grant S, Frampton G, Petrescu AD, Kain J, Williams E, et al. FXR-Mediated Cortical Cholesterol Accumulation Contributes to the Pathogenesis of Type A Hepatic Encephalopathy.Cell Mol Gastroenterol Hepatol. 2018;6:47–63. [DOI] [PubMed] [PMC]
Ye W, Bai X, Zhao Y, Du Z, Liu F, Wang YD, et al. Farnesoid X receptor activation alleviates hepatic encephalopathy by improving hepatic ammonia metabolism in murine models.Biochim Biophys Acta Mol Basis Dis. 2025;1871:167750. [DOI] [PubMed]
Saito Y, Chen S, Ikemoto T, Teraoku H, Yamada S, Morine Y, et al. Farnesoid X receptor agonist accelerates ammonium metabolism of mesenchymal stem cell-derived hepatocyte-like cells.J Med Invest. 2025;72:54–9. [DOI] [PubMed]
Petrescu AD, DeMorrow S. Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury.Cells. 2021;10:1846. [DOI] [PubMed] [PMC]
Pathak P, Liu H, Boehme S, Xie C, Krausz KW, Gonzalez F, et al. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.J Biol Chem. 2017;292:11055–69. [DOI] [PubMed] [PMC]
Liang H, Matei N, McBride DW, Xu Y, Zhou Z, Tang J, et al. TGR5 activation attenuates neuroinflammation via Pellino3 inhibition of caspase-8/NLRP3 after middle cerebral artery occlusion in rats.J Neuroinflammation. 2021;18:40. [DOI] [PubMed] [PMC]
McMillin M, Frampton G, Tobin R, Dusio G, Smith J, Shin H, et al. TGR5 signaling reduces neuroinflammation during hepatic encephalopathy.J Neurochem. 2015;135:565–76. [DOI] [PubMed] [PMC]
Guo C, Chen WD, Wang YD. TGR5, Not Only a Metabolic Regulator.Front Physiol. 2016;7:646. [DOI] [PubMed] [PMC]
Coretti L, Buommino E, Lembo F. The aryl hydrocarbon receptor pathway: a linking bridge between the gut microbiome and neurodegenerative diseases.Front Cell Neurosci. 2024;18:1433747. [DOI] [PubMed] [PMC]
Gil-Gómez A, Muñoz-Hernández R, Martínez F, Jiménez F, Romero-Gómez M. Hepatic encephalopathy: experimental drugs in development and therapeutic potential.Expert Opin Investig Drugs. 2024;33:1219–30. [DOI] [PubMed]
Xu X, Zhu T, Jing C, Jiang M, Fu Y, Xie F, et al. Hepatic encephalopathy treatment after transjugular intrahepatic portosystemic shunt: a new perspective on the gut microbiota.Front Med (Lausanne). 2025;12:1423780. [DOI] [PubMed] [PMC]
Maharshi S, Sharma BC. Prophylaxis of hepatic encephalopathy: current and future drug targets.Hepatol Int. 2024;18:1096–109. [DOI] [PubMed]
Torre A, Córdova-Gallardo J, Martínez-Sánchez FD. Hepatic encephalopathy: risk identification and prophylaxis approaches.Metab Brain Dis. 2025;40:138. [DOI] [PubMed]
Hoilat GJ, Suhail FK, Adhami T, John S. Evidence-based approach to management of hepatic encephalopathy in adults.World J Hepatol. 2022;14:670–81. [DOI] [PubMed] [PMC]
Dhiman RK, Thumburu KK, Verma N, Chopra M, Rathi S, Dutta U, et al. Comparative Efficacy of Treatment Options for Minimal Hepatic Encephalopathy: A Systematic Review and Network Meta-Analysis.Clin Gastroenterol Hepatol. 2020;18:800–12.e25. [DOI] [PubMed]
Hassouneh R, Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment.J Clin Med. 2021;10:330. [DOI] [PubMed] [PMC]
Williams E, Chu C, DeMorrow S. A critical review of bile acids and their receptors in hepatic encephalopathy.Anal Biochem. 2022;643:114436. [DOI] [PubMed] [PMC]
Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease.Nature. 2019;575:505–11. [DOI] [PubMed] [PMC]
Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae.Cell Metab. 2019;30:675–88.e7. [DOI] [PubMed]
Afecto E, Ponte A, Fernandes S, Silva J, Gomes C, Correia J, et al. Fecal microbiota transplantation in hepatic encephalopathy : a review of the current evidence and future perspectives.Acta Gastroenterol Belg. 2021;84:87–90. [DOI] [PubMed]
Li X, Xiao Y, Zhu Y, Li P, Zhou J, Yang J, et al. Regulation of autophagy by ST3GAL2-mediated α2-3 sialylated glycosphingolipids in hepatic encephalopathy.Int J Biol Macromol. 2024;278:135196. [DOI] [PubMed]
Zhang Y, Luan H, Song P. Bilirubin metabolism and its application in disease prevention: mechanisms and research advances.Inflamm Res. 2025;74:81. [DOI] [PubMed]
Fagan A, Gallagher ML, Mousel T, Davis BC, Fuchs M, Puri P, et al. Artificial Intelligence Evaluation of Stool Quality Guides Management of Hepatic Encephalopathy Using a Smartphone App.Am J Gastroenterol. 2024;119:977–81. [DOI] [PubMed]
Sordi Chara B, Hara KS, Penrice D, Schmidt KA, Kassmeyer BA, Anstey J, et al. Artificial Intelligence-Enabled Stool Analysis for Lactulose Titration Assistance in Hepatic Encephalopathy Through a Smartphone Application.Am J Gastroenterol. 2024;119:982–6. [DOI] [PubMed]
Chen ZL, Wang C, Wang F. Revolutionizing gastroenterology and hepatology with artificial intelligence: From precision diagnosis to equitable healthcare through interdisciplinary practice.World J Gastroenterol. 2025;31:108021. [DOI] [PubMed] [PMC]
Wu T, Louissaint J. Emerging digital technologies to help patients with cirrhosis.Clin Liver Dis (Hoboken). 2024;23:e0209. [DOI] [PubMed] [PMC]
Louissaint J, Vargas HE. Picture Perfect: Artificial Intelligence in the Management of Hepatic Encephalopathy.Am J Gastroenterol. 2024;119:801–2. [DOI] [PubMed]
Qiu S, Zhao Y, Hu J, Zhang Q, Wang L, Chen R, et al. Predicting the 28-day prognosis of acute-on-chronic liver failure patients based on machine learning.Dig Liver Dis. 2024;56:2095–102. [DOI] [PubMed]
Bajaj JS, O’Leary JG, Jakab SS, Fagan A, Sikaroodi M, Gillevet PM. Gut microbiome profiles to exclude the diagnosis of hepatic encephalopathy in patients with cirrhosis.Gut Microbes. 2024;16:2392880. [DOI] [PubMed] [PMC]
Sah AK, Afzal M, Elshaikh RH, Abbas AM, Shalabi MG, Prabhakar PK, et al. Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes.Life (Basel). 2025;15:779. [DOI] [PubMed] [PMC]
Thiele M, Villesen IF, Niu L, Johansen S, Sulek K, Nishijima S, et al.; MicrobLiver consortium; GALAXY consortium. Opportunities and barriers in omics-based biomarker discovery for steatotic liver diseases.J Hepatol. 2024;81:345–59. [DOI] [PubMed]
Ahmed MI, Spooner B, Isherwood J, Lane M, Orrock E, Dennison A. A Systematic Review of the Barriers to the Implementation of Artificial Intelligence in Healthcare.Cureus. 2023;15:e46454. [DOI] [PubMed] [PMC]
Miwa T, Tsuruoka M, Ueda H, Abe T, Inada H, Yukawa-Muto Y, et al. Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.J Gastroenterol. 2025;60:866–76. [DOI] [PubMed] [PMC]
